Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Arpida logo — company profile

Arpida

Founded 1997 31 employees Private Equity Total: $55.00M Biopharma, Biotechnology +2

General Information

Company Name Arpida
Founded Year 1997
Employees 31
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Private Equity
Social

BounceWatch is an independent company data service, not affiliated with Arpida. To contact Arpida, visit arpida.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Arpida compare?

A PDF of Arpida and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Arpida soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Arpida

Arpida is a biopharmaceutical company (SIX: ARPN) headquartered in Reinach, near Basel, Switzerland with operations in Switzerland and the USA. Established in 1997, the company focuses on novel drugs that address the growing issue of microbial resistance. Arpida’s primary product candidate is intravenous iclaprim, an antibiotic tailored for severe infections necessitating hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The company operates within the Biopharma, Biotechnology, Health Care, and Pharmaceutical sectors. Its most recent investment was a Private Equity Round secured on 01 December 2004, with Cita Investissement participating as the investor.

Business keywords: biopharmaceutical, antibiotic, MRSA, drug development, microbial resistance, infections, IV iclaprim, medical research, pharmaceutical industry, clinical trials, Switzerland, USA, innovation

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Private Equity Round Undisclosed 1
Cita Investissement
Cita Investissement
01 Dec 2004
Series B Fr.40.00M 6
3i Group HealthCap Alta Berkeley Venture Partners
3i Group, HealthCap +4
23 Oct 2000
Series A Fr.15.00M 3
3i Group Alta Berkeley Venture Partners
3i Group, Alta Berkeley Venture Partners +1
01 Jul 1998
Seed Round Undisclosed -
01 Dec 1997

Arpida Alternatives & Competitors

View All Alternatives
Arpida vs
Arrevus
Arrevus

Conquering antibiotic resistance by targeting critical diseases with innovative DPCs.

Grant
Biotechnology, Pharmaceutical
Arpida vs
Microbion Corporation
Microbion Corporation United States

Developing a disruptive new class of therapeutic drugs for the treatment of rare, chronic, and serio...

Venture round
16 employees
Biotechnology, Health Care
Arpida vs
Allecra Therapeutics
Allecra Therapeutics

Our Mission: Answering the call to action to fight antibiotic resistance

Series B
7 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Arpida

Arpida (SIX: ARPN) is a biopharmaceutical company headquartered in Reinach, near Basel, Switzerland with operations in Switzerland and the USA. It focuses on novel drugs that seek to overcome the growing problem of microbial resistance. Arpida’s leading product candidate is intravenous iclaprim, an...
Arpida was founded in 1997.
Arpida operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on biopharmaceutical, antibiotic, MRSA and drug development.
Arpida has approximately 31 employees.
Arpida has completed 4 funding rounds, raising a total of $55.00M. The latest funding stage is Private Equity.
Top alternatives and competitors to Arpida include Arrevus, Microbion Corporation, Allecra Therapeutics, SelectX Pharmaceuticals, ASLAN Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Arpida and Arrevus are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Arpida, https://bouncewatch.com/company/arpida, updated 14 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes